Schaper Benz & Wise Investment Counsel Inc. WI Takes Position in Avanos Medical Inc (AVNS)
Schaper Benz & Wise Investment Counsel Inc. WI purchased a new position in Avanos Medical Inc (NYSE:AVNS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,992 shares of the company’s stock, valued at approximately $205,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Oregon Public Employees Retirement Fund bought a new position in shares of Avanos Medical during the second quarter worth $1,033,000. Public Employees Retirement System of Ohio bought a new position in shares of Avanos Medical during the second quarter worth $136,000. McQueen Ball & Associates Inc. bought a new position in shares of Avanos Medical during the third quarter worth $268,000. CENTRAL TRUST Co bought a new position in shares of Avanos Medical during the third quarter worth $167,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Avanos Medical during the third quarter worth $704,000. Institutional investors and hedge funds own 83.87% of the company’s stock.
Shares of NYSE:AVNS traded down $1.27 during midday trading on Friday, reaching $59.58. 7,353 shares of the company were exchanged, compared to its average volume of 278,696. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.18 and a current ratio of 2.48. Avanos Medical Inc has a one year low of $41.51 and a one year high of $72.96. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of 25.43 and a beta of 1.76.
A number of equities analysts recently weighed in on AVNS shares. Zacks Investment Research upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research report on Thursday, August 9th. Barclays started coverage on shares of Avanos Medical in a research report on Monday. They set an “equal weight” rating and a $69.00 target price for the company. Raymond James upgraded shares of Avanos Medical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 21st. KeyCorp upped their target price on shares of Avanos Medical from $66.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Finally, Morgan Stanley upped their target price on shares of Avanos Medical from $60.00 to $62.00 and gave the stock an “underweight” rating in a research report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Avanos Medical currently has a consensus rating of “Hold” and a consensus target price of $69.25.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
See Also: Retained Earnings
Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical Inc (NYSE:AVNS).
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.